Abstract. Cleft palate is among the most common congenital disorders, and can be induced by exposure to all-trans retinoic acid (atRA) during mice and human embryogenesis.
Introduction
Cleft palate is one of the most common congenital craniofacial disorders (1, 2) . The palate consists of two parts, the primary and the secondary palate. Secondary palatal development involves several steps: First, the two palatal shelves grow vertically, and then reorient to a horizontal position above the tongue. Subsequently, the opposite palatal shelves come into contact and fuse (3) . Vertical growth and elevation are important during palatal development. When palatal shelf growth and elevation fail to occur, a cleft palate forms.
Retinoic acid (RA), which is the active metabolite of vitamin A, is essential for numerous biological processes and serves a critical role in vertebrate morphogenesis (4) . Conversely, exogenous RA is a potent teratogen during embryonic development. According to the stage, i.e. early or late, of palatogenesis, excess RA administration can induce cleft palate of varying degrees. Exposure of pregnant mice to RA on embryonic day (E)10 has been reported to result in small palatal shelves that fail to elevate, whereas RA exposure on E12 has been demonstrated to lead to normal-sized palatal shelves that can form contacts but are incapable of fusion (5, 6) .
Notch signaling is an evolutionarily conserved signaling pathway in mammals that serves important roles in the regulation of cellular survival and apoptosis (7, 8) . Notch signaling is activated when the Notch receptor (Notch1-4) is bound by a ligand, such as Jagged1 and 2 or Delta-like-1, -3 and -4, which is expressed on the surface of an adjacent cell. The functions of Notch2 and Notch3 have been studied extensively in vascular smooth muscle cells; however, the complex roles of Notch2 in vascular smooth muscle cell proliferation have yet to be elucidated. A previous study identified the differential regulation of the unique functions of Notch2 and Notch3 during vascular smooth muscle cell proliferation (9) . In addition, it has previously been reported that Notch2 may inhibit vascular smooth muscle cell proliferation through the regulation of the cyclin-dependent kinase inhibitor p27 kip1 (10) . The relationship between Notch and RA has also been investigated. RA treatment was demonstrated to induce cell cycle arrest at G 1 phase in glioblastoma stem cells, via downregulating cyclin D1 and upregulating p27 expression (11) . Jagged2-Notch1 signaling has been implicated in physiological palatogenesis during embryonic development (12) . However, the role of Notch2 following RA exposure during palatal development has yet to be elucidated. The aim of the present study was therefore to investigate the role of Notch signaling in RA-induced mouse embryonic palate mesenchymal (MEPM) cell proliferation inhibition.
Materials and methods
Antibodies. Anti-Notch1 (ab52627), anti-p21 (ab109199), anti-cyclin D1 (ab134175) and anti-Ki-67 (ab15580) antibodies were purchased from Abcam (Cambridge, UK . A fixed area near the tip of the palatal shelf (20x20 µm) was selected for quantification using Image-Pro Plus 6.0 software (Media Cybernetics, Inc., Rockville, MD, USA). Briefly, in the fixed areas, positive immunostaining for Notch2 was selected, and the integrated optical density (OD) was measured. The % of relative OD units compared with control was calculated as described previously (13) .
Collection of palatal shelves and isolation of MEPM cells.
Embryonic palatal shelves were isolated from atRA-treated or untreated pregnant female mice between E12.5 and E14.5. The epithelium was removed using tungsten needles following incubation in 1 U/ml dispase II (Roche Diagnostics, Indianapolis, IN, USA) at 37˚C for 20 min. The palatal shelves were digested in 0.25% trypsin for 3 min and agitated to obtain a cell suspension. Suspended cells were collected for reverse transcription-quantitative polymerase chain reaction (RT-qPCR) or western blot analysis.
Cell culture and treatments. Primary MEPM cells were isolated from the palatal shelves of control untreated mice on E13.5 and cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA), supplemented with 10% fetal bovine serum (FBS; Invitrogen; Thermo Fisher Scientific, Inc.). Cells were maintained at 37˚C in a 5% CO 2 atmosphere. The culture medium was replaced every 24 h. BMS493, an RA receptor (RAR) antagonist, was purchased from Sigma-Aldrich (Merck KGaA). MEPM cells were treated with 3 µM BMS493 or with 0, 1, 5 and 10 µM atRA, for 48 h at 37˚C.
RNA interference. Notch2 small interfering (si)RNA and control siRNA were transfected into cultured MEPM cells using Lipofectamine ® RNAiMAX Reagent in Opti-MEM reduced serum medium (Invitrogen; Thermo Fisher Scientific, Inc.) at 50 nM, according to the manufacturer's protocol. The control siRNA (Lot:0,0806) was purchased from Guangzhou RiboBio Co., Ltd. (Guangzhou, China). The Notch2 siRNA was chemically synthesized by Guangzhou RiboBio Co., Ltd., with the following sequence: CCA GTA CAG TGA AAT GTT T. A total of 24 h post-transfection, cells were treated with atRA (5 µM) in DMEM without FBS for 48 h at 37˚C and collected for analysis.
Western blot analysis. Proteins of interest isolated from atRA-treated or control embryos and cultured MEPM cells were analyzed using western blot analysis, as previously described (14) . Total protein was extracted from palatal shelves and MEPM cells using radioimmunoprecipitation assay lysis buffer (Thermo Fisher Scientific, Inc.) supplemented with protease and phosphatase inhibitors at 4˚C for 30 min, and centrifuged at 15,000 x g at 4˚C for 30 min. Protein content was determined by bicinchoninic acid assay. Equal amounts (30 µg) of extracted protein samples were separated by 10% SDS-PAGE and transferred onto nitrocellulose membranes (EMD Millipore, Billerica, MA, USA). The membranes were blocked with 5% evaporated skimmed milk at 37˚C for 1 h and incubated with primary antibodies (Notch1, Notch2, Notch3, P21, cyclinD1, p-ERK, ERK, ki67, GAPDH; 1:1,000 dilution) in 5% evaporated skimmed milk at 4˚C for 12 h, and horseradish peroxidase-conjugated secondary antibody (1:2,000 dilution; cat. no. 7074s; Cell Signaling Technology, Inc.) in 5% evaporated skimmed milk at 37˚C for 1 h. Protein bands were visualized using an enhanced chemiluminescence kit (Cell Signaling Technology, Inc.) and the ImageQuant Las4000mini system (GE Healthcare Life Sciences, Chalfont, UK). GAPDH was used as an internal control. The signal intensities were quantified using ImageJ version 1.48u software (National Institutes of Health, Bethesda, MD, USA) (15) .
RT-qPCR. Total RNA was extracted from MEPM cells using TRIzol ® reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. cDNA was reverse transcribed from 1 µg of total RNA using a Transcriptor First-Strand cDNA Synthesis kit (Roche Diagnostics, Burgess Hill, UK). qPCR was performed using the SYBR-Green I reaction mix (Roche Diagnostics), as per the manufacturer's instructions. The thermocycling conditions were as follows: 95˚C for 5 min, then 40 cycles of 95˚C for 10 sec, 60˚C for 20 sec, and 72˚C for 20 sec. qPCR reactions were performed in a Roche Light Cycler 480 system (Roche Diagnostics) The following primers were used: β-actin, forward 5'-TCA C-CCA CAC TGT GCC CAT CTA CGA-3' and reverse 5'-GGA TGC CAC AGG ATT CCA TAC CC-A-3'; RARα, forward 5'-TCA GTG CCA TCT GCC TCA T-3' and reverse 5'-CGT AGA CTT T-CA GTG CTT CCA G-3'; RARβ, forward 5'-GTG CCA TCT GTT TAA TCT GTG G-3' and reverse 5'-TGC TGG GTC GTC GTT TTC-3'; RARγ, forward 5'-ATA CCC CAG AGC AG-G ACA CTA-3' and reverse 5'-GGC AAA GGC AAA GAC GAG-3'; Notch1, forward 5'-AAC ATG GGC CGT ACT CCG TTA-3' and reverse 5'-AGC CAG GAT CAG TGG AGT TGT G-3'; Notch2, forward 5'-ACA AGT GAA GTG CAG GAG AGG GG-3' and reverse 5'-CAG CGG C-AGG AAT AGT GAG GAG-3'; and Notch3, forward 5'-CTC TGT GGT GAT GCT GGA GAT TGA-3' and reverse 5'-TGC TGA CAA GGC TCC CAG GTA G-3'. Target genes were normalized to β-actin, and relative fold changes in mRNA expression were calculated using the formula 2 -ΔΔCq (16).
Proliferation assay. A Cell Counting Kit-8 (Wylton Chemistry Co., Ltd., Tongren, China) assay was used to assess cellular proliferation. Primary MEPM cells were seeded into a 96-well collagen-coated plate (1x10 4 cells/well) and treated with control siRNA, control siRNA+atRA (5 µM), Notch2 siRNA and Notch2 siRNA+atRA (5 µM), prior to measuring proliferation as per the kit's instructions. Bead implantation in palatal shelves. Palatal shelves of E13.5 mouse embryos were gently removed from the maxilla in cold PBS (Invitrogen; Thermo Fisher Scientific, Inc.). Dissected palatal shelves were placed on MF-Millipore ™ membrane filters. Biggers, Gwatkin, and Judah (Fitton-Jackson modification) medium (BGJb; Invitrogen; Thermo Fisher Scientific, Inc.) was used for culture. Anion exchange resin beads (Dowex ® 1x4, 100-200 mesh; Sigma-Aldrich; Merck KGaA) served as atRA carriers. Following incubation in 20-50 µM atRA at room temperature for 45 min, the beads were washed with BGJb medium for 15 min. Control beads were treated with vector alone. Beads were implanted into palate shelves using fiber probe under a stereomicroscope (Carl Zeiss AG). Samples were cultured for 48 h and then collected for immunohistochemical analysis.
Statistical analyses. The statistical significance of the difference between groups was assessed by Student's t-test and one-way analysis of variance, using SPSS 19.0 software (IBM SPSS, Armonk, NY, USA). Data was expressed as mean ± standard deviation. All experiments were repeated at least 3 times. P<0.05 was considered to indicate a statistically significant difference.
Results
atRA exposure on E10.0 induces cleft palate in mouse embryos. atRA exposure on E10.0 was demonstrated to induce cleft palate in 99% of the embryos (99/100), whereas no embryos exhibited cleft palate in the control group (0/100). H&E staining revealed the morphological changes of palatal shelves on E12.5, 13.4, 14.5 and 16.5 in atRA-treated embryos and controls (Fig. 1A) . On E12.5, atRA-exposed embryos exhibited palatal shelves of smaller volume compared with controls, as determined by visual observation. On E13.5, palatal shelves grew vertically and no differences were apparent between atRA-treated and control embryos. On E14.5, palatal shelves elevated and contacted with the opposing palates in control embryos, whereas atRA-exposed embryos exhibited unelevated shelves. On E16.5, a firm palate formed and the medial edge epithelium disappeared in untreated embryos; however, in atRA-exposed embryos, palatal shelves failed to elevate and a cleft palate developed.
Notch2 expression is upregulated in MEPM cells from atRA-treated embryos via RAR activation.
To identify atRA-induced Notch signaling events impairing palatogenesis, protein expression levels of Notch1, Notch2 and Notch3 were assessed in MEPM cells isolated from atRA-treated and untreated embryos between E12.5 and E14.5. Immunohistochemistry revealed that Notch2 expression was elevated in the atRA-treated embryos compared with in the controls (P<0.05; Fig. 1B) . Notably, no significant differences were detected in the expression of Notch1 and Notch3 between atRA-exposed and control embryos (Fig. 2) . Furthermore, Notch mRNA and protein expression levels were assessed using western blot analysis (Fig. 3) and RT-qPCR (Fig. 4) . In accordance with the results of immunohistochemical analysis, Notch2 mRNA and protein expression levels were significantly upregulated in atRA-treated embryos compared with in the control group. Conversely, protein ( Fig. 3B and D) and mRNA ( Fig. 4A and C) expression levels of Notch1 and Notch3 were not significantly different between atRA-exposed embryos and controls.
To investigate whether RAR activation was implicated in the atRA-induced Notch2 upregulation in MEPM cells, RAR mRNA expression levels were assessed in the presence of various atRA concentrations using RT-qPCR (Fig. 5) . mRNA expression levels of RARβ and RARγ increased significantly following atRA treatment compared with untreated cells (P<0.05; Fig. 5 ), but no significant differences were observed in the mRNA expression levels of RARα. To further investigate whether the upregulation of Notch2 resulted from the direct action of atRA on RARs, the RAR antagonist BMS493 was applied to MEPM cells prior to atRA treatment. Notably, Notch2 expression was downregulated following pretreatment with BMS493 (P<0.05; Fig. 6 ).
MEPM cellular proliferation is suppressed in atRA-treated embryos. To examine the proliferation rate of MEPM cells in control and atRA-exposed embryos, the expression of Ki-67 was assessed in MEPM cells isolated from E12.5-14.5 embryos, using immunohistochemistry. There were fewer Ki-67-positive MEPM cells in atRA-treated embryonic tissue compared with in control tissue on E12.5 and 13.5 (P<0.05); however, no significant difference was observed on E14.5 (Fig. 7A) . Western blot analysis demonstrated a downregulation in Ki-67 protein expression levels in MEPM cells in E12.5 and 13.5 atRA-exposed embryos compared with in age-matched controls (P<0.05; Fig. 7B ).
To further investigate downstream Notch signaling events, total and p-ERK protein expression levels were assessed. p-ERK was significantly downregulated in E12.5 and 13.5 atRA-treated embryos compared with in the control group (P<0.05). Cell cycle-related proteins p21 and cyclin D1 were also analyzed. p21 protein expression levels were increased, whereas cyclin D1 levels were decreased in the atRA-treated group compared with in controls between E12.5 and E14.5 (P<0.05; Fig. 7B ).
Notch2 silencing attenuates atRA-induced inhibition of MEPM cellular proliferation.
To investigate whether Notch2 may be involved in atRA-induced inhibition of MEPM cellular proliferation, Notch2 siRNA was used. atRA was demonstrated to decrease p-ERK protein expression levels; however, Notch2 knockdown attenuated the atRA-induced p-ERK downregulation (P<0.05; Fig. 8A ). As a potential signaling pathway downstream of ERK, p21 expression levels were decreased in the Notch2 knockdown group compared with in the control group (P<0.05; Fig. 8A ). Conversely, cyclin D1 protein levels increased in MEPM cells not expressing Notch2 compared with in control cells (P<0.05; Fig. 8A ).
In the absence of Notch2, MEPM cells treated with atRA exhibited increased proliferation compared with control cells (P<0.05; Fig. 8B ). Notch2 knockdown was demonstrated to partially attenuate the atRA-induced inhibition of MEPM cellular proliferation. Western blot analysis of Ki-67 protein expression levels also supported these results (P<0.05; Fig. 8A ).
Stimulation of Notch2 expression in palatal shelves by atRA.
Palatal shelves isolated from E13.5 embryos were cultured for 48 h with implanted beads soaked in atRA or control vector (Fig. 9A) . Notch2 protein expression was assessed using immunohistochemistry. Notch2 expression appeared to be upregulated in MEPM cells surrounding the atRA-releasing bead compared with in control cells (P<0.05; Fig. 9B ). Conversely, Ki-67 expression appeared to be decreased in atRA-exposed palatal shelves compared with in controls (P<0.05; Fig. 9C ).
Discussion
In the present study, the effects of atRA on MEPM cells were investigated during palatogenesis. The present results indicated that atRA inhibited MEPM cellular proliferation in vitro and in vivo. Furthermore, Notch2 appeared to be involved in the atRA-mediated inhibition of cellular proliferation.
It has previously been reported that Notch signaling is inhibited during RA-induced inhibition of glioblastoma stem cell growth (11) . Notably, the present study revealed that Notch2 expression was upregulated in atRA-treated E12.5-14.5 embryos, whereas Notch1 and Notch3 expression remained unaltered. In accordance with the results of a previous study (17) , p21 expression was upregulated and cyclin D1 expression was downregulated in atRA-treated E12.5-14.5 embryos. Since ERK signaling is implicated in the regulation of cellular proliferation, total and p-ERK levels were assessed. p-ERK protein expression levels were revealed to be decreased in atRA-treated E12.5-14.5 embryos.
It is well established that the effects of atRA are mediated by the activation of RARs (18) . Therefore, the present study investigated whether Notch2 upregulation may result from the direct action of atRA on RARs. The present results demonstrated that RAR inhibition prevented the atRA-induced Notch2 upregulation in MEPM cells. The upregulation of Notch2 observed during the cellular response to atRA suggested that Notch2 signaling may participate in the mechanisms underlying atRA-induced cleft palate. Other pathways may also participate in this process. Previous studies had indicated that Smad2/3 and Wnt/β-catenin signaling were involved in atRA-induced MEPM growth inhibition (14, 18) . ERK1/2 signaling is implicated in the regulation of cellular proliferation (19, 20) . The ERK pathway has been reported to serve a critical role in cellular proliferation, via inducing the transcription of cyclin D1 (21) . In addition, ERK2 has been demonstrated to enhance cellular proliferation via promoting p21 degradation (22) . A previous study revealed that the regulation of MEK/ERK signaling by Notch2 is implicated in vascular smooth muscle cell proliferation (9) . In the present study, knockdown of Notch2 increased p-ERK protein expression levels and attenuated the atRA-induced p-ERK downregulation. In addition, p21 expression was downregulated, whereas cyclin D1 expression was upregulated following Notch2 silencing. These results suggested that atRA, via the upregulation of Notch2 protein expression, may inhibit the proliferation of MEPM cells, possibly through the implication of ERK signaling pathways.
In summary, administration of atRA inhibited the proliferation of mouse embryo mesenchymal cells and blocked the elevation of palatal shelves, thus leading to a cleft palate.
The present study identified that Notch signaling was involved in atRA-induced inhibition of MEPM cell proliferation. These findings highlighted the molecular and teratogenic actions of atRA, and might contribute to the development of potential novel treatments for cleft palate in the future.
